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Abstract: 
Background: Surgical wound infection is an internationally recognized 
complication which is expected to get cured in few days time. Lack of antibiotic 
policies added to the existing chaos in free market policies is expected to end up 
with mysterious resistant organisms soon in future. 
Objectives: To report our experience with 52 key hole protracted surgical wound 
infections in 23 patients.  
Patients and methods: Demographic data of patients who suffered post operative subcutaneous 
wound nodules following minimal access surgery, duration of the disease and its clinical 
manifestations as well as results of investigations were collected and analysed.    
Results:   Two males and 21 females, age range 27-65 (median 42) years had 32 key-hole wound 
nodules and 20 persistent discharging wounds that had appeared in an average but latent period of 
nine weeks (range three weeks to sixmonths after surgery). Only two cultures were positive for 
Mycobacterium chelonae.  
Conclusion: Mycobacterium chelonae should be suspected in protracted surgical wounds and 
treated promptly with meticulous frequent dressings, wound excision and clarithromycin plus 
ceftazidime. 
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ycobacterium is one of the 
oldest microorganism and 
one of the best-studied 
bacteria. The genus mycobacterium 
compromises the acid-fast bacilli due to their 
impermeability by certain dyes and stains1. 
The name mycobacterium, meaning fungus-
like bacterium, is derived from the mould like 
appearance of M tuberculosis when growing 
in liquid media. On the basis of growth rate, 
catalase and niacin production, and 
pigmentation in light or dark, mycobacteria 
are classified into members of the 
Mycobacterium tuberculosis complex (M 
tuberculosis, M bovis, M africanum, M 
microtii) and Mycobacterium Other Than 
Tuberculosis (MOTT). Gene probe 
technology now facilitates this distinction1,2. 
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Objectives: To report our experience with 52 
keyhole protracted surgical wound infections 
in 23 patients.  
Patients and Methods: Data of patients 
operated in three different health facilities 
from June 2007 through November 2007 who 
presented to us with post operative 
subcutaneous wound nodules, and/or delayed 
wound discharge 3 weeks or more after the 
primary surgery were interviewed for the 
symptoms related to the keyhole surgical 
wounds that forced these patients to come 
back for further advise and treatment. The 
physique of the patients, presence of keyhole 
wound discharge or nodule, consistency of the 
nodules, type of antibiotics used, results of 
wound swap culture, histopathology of wound 
excision,  duration of the disease and response 
to antibiotics were collected and analysed. 
Results:  
From June 2007- November 2007, 23 
patients came back looking for medical advice 
for problems that developed in the surgical  
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pore wounds of the operation they 
have had. They were two males and 21 
females. Age range was 27-65 (median 42) 
years. Their average body weight was <35 
except five ladies who had body mass index 
>35 each. 16 patients had laparoscopic 
cholecystectomy (LC) for chronic calcular 
cholecystitis. Five cases had LC for acute 
cholecystitis, one mucocele of gallbladder and 
one open surgery for acute appendicitis. LC 
was performed via four conventional pores. 
All patients were discharged 24 hours 
following surgery. All patients except that 
who had appendicectomy (medical doctor) 
reported in follow up one week after their 
discharge with nice healed wound, no pain, 
local tenderness or fever.  All patients 
admitted that they had recovered nicely, were 
satisfied with the result of surgery and had 
resumed their routine life activities few days 
after discharge. The medical doctor resumed 
his work but called five weeks after surgery 
describing presence of painful nodules at the 
vicinity of his appendicectomy wound.  
            In an average of a few weeks to six 
months patients started to come back for 
medical advice because of low grade fever in 
five, generalized weakness, malaise with 
either painful nodules sour on touch in eight 
or protracted wound discharge in 10 patients. 
The average latent period was nine weeks 
(range three weeks to six months).  
Initial management: Swabs were taken from 
five wounds for culture and sensitivity then 
wounds were kept on daily dressing with 
normal saline, diluted Betadine –saline 
solution (1:10 V/V) and/or ciprofloxacin tabs 
500mg bid. 12 wounds healed in an average 
period of three weeks. Of these four wounds 
broke spontaneously with little discharge 
causing patient discomfort. All nodules 
regressed on treatment except 11 nodules in 
the five ladies with > 35 each were excised 
and sent for histopathology.  
The result of 11 wound cultures was 
Klepsiella spp. in five, Staph. Aureus in three 
and no growth in another three wounds 
discharge cultures. Histopathology reported 
features of non-specific infection with non- 
 
casiating granuloma seen in five out of nine 
wound excisional biopsies. However, the 
result of the wound culture of the 
appendicectomy wound in Rhyadh, KSA 
revealed Mycobacterium chelonae and the 
minimum inhibitory test was done in Mayo’s 
clinic showed that M chelonae is sensitive to 
clarithromycin and Amikacin. After this result 
two weeks and 2 months respectively wound 
cultures in Fedail Hospital Microbiology 
Laboratory, Khartoum, Sudan was successful 
in isolating M chelonae in culture colonies 
(Fig 1 & Fig 2a and b).  
Fig 1: LJ culture showing cream-colour  




Fig 2 a: High power microscopic appearance 
of M chelonae with ZN stain  
 
 
Literature was reviewed and accordingly 
treatment was instituted with Clarithromycin 
500mg tablets bid in 16 patients for six weeks 
and Clarithromycin in the same dose 
combined with ceftazidime one gram i.v daily 
for three weeks in another seven patients. 
This later regimens combined with wound  
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excision resulted in complete cure. During 
wound excision the nodule was found in all 
cases of wound excision to be confined to the 
subcutaneous fat and adherent to the 
apponeurosis of the external oblique muscle.  
 
Fig 2 b: Low power microscopic appearance 
of M chelonae with ZN stain 
 
Discussion:    
Increased attention to 
mycobacteriology in the first half of 20th 
century, led to recognition of a number of 
clinical mycobacterial isolates that had 
colonial characteristic different from M 
tuberculosis. In the 1950 Ernest Runyon and 
Timpe provided convincing evidence for the 
role of these mycobacteria in human disease 
and classified these mycobacteria based on 
growth rate and pigment production on solid 
media into four broad groups: Group I 
(photochromogenics), Group II 
(scotochromogenics), Group III 
(nonchromogenics) and Group IV (rapid 
growers)2,3.  
Mycobacterium Other Than 
Tuberculosis (MOTT) is free-living 
organisms with no significant person to 
person spread but is resistant to anti-
tuberculous drugs. Medical important Runyon 
group IV (rapidly growing mycobacteria) 
includes Mycobacterium fortuitum, M. 
chelonae/abscessus, M. mucogenicum and M. 
smegmatis groups2,3. M fortuitum and M 
chelonae are major pathogen in the latter 
group. They were recovered readily from soil, 
dust and water. They have been isolated from 
tap water, municipal water supplies, and 
moist area in the hospital, reagents and wash 
solutions used in the hospitals etc. The source  
 
of surgical contamination has often been 
obscure4.   
Advances in the knowledge of 
genetics, cell structure and phenotypic 
properties of old and newly discovered strains 
of mycobacteria have advanced the 
knowledge beyond the neat packing of 
species under classic Runyon system of 
classification5. Woods and Washington have 
suggested a clinically oriented classification 
of mycobacteria. Nevertheless, the 
traditionally trained mycobacteriologist will 
continue classifying MOTT into four Runyon 
group5. 
M chelonae is one of the group of the 
rapidly growing mycobacteria classified as 
Runyon Group IV that can cause various 
clinical syndromes, including lung disease, 
local cutaneous disease, osteomyelitis, joint 
infections, and ocular disease such as; 
keratitis or corneal ulcers. With the exception 
of lung disease, these syndromes commonly 
develop after trauma. M chelonae is a rare 
cause of isolated lymphadenitis and 
endocarditis. Disseminated disease, usually 
with disseminated skin and soft tissue lesions, 
occurs almost exclusively in cases suffering 
from immuno-suppression, especially AIDS2. 
Soft-tissue infections caused by M. chelonae 
typically manifest initially as slightly tender 
nodules with scanty discharge and minimal 
surrounding cellulites; systemic 
manifestations often are absent. Therefore, the 
clinical presentation in our patients is in 
keeping with that described in the literature. 
The indolent course typical of these 
infections, together with a low index of 
suspicion and failure to request or perform the 
appropriate diagnostic tests (e.g., acid-fast 
staining), can make timely diagnosis of M. 
chelonae infections and treatment difficult9. 
This explains why we were able to suspect 
and isolate M chelonae very late after we got 
the diagnosis from Ryiadh, KSA. M chelonae 
is an extremely rare cause of infection among 
humans and is difficult to treat. This is why 
we opted to excise all wounds that did not 
respond adequately to treatment and regular 
dressings.   
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          Although M. chelonae was identified as 
the cause of approximately 10% of 
nosocomial outbreaks attributed to rapidly 
growing mycobacteria4, 5. This probably 
explains our first reported epidemic in Sudan. 
To our best of knowledge this is the first time 
for M. chelonae to be isolated and reported in 
Sudan. M. chelonae, resist the activity of 
disinfectants and biocides such as 
organomercurials, chlorine, and alkaline 
glutaraldehyde. Reports from India10 showed 
an outbreak associated with the water used to 
rinse endoscopes for laparoscopic surgery, 
resulting in 35 patients related infection 
caused by M chelonae. Up-to-date no human-
to-human transmission has been documented5, 
10. Data from US Centers for Disease Control 
and Prevention (CDC) in between 1993-1996 
showed, 0.93-2.64 cases per million 
populations for M chelonae related 
infection11.  
M chelonae can be suspected if 
growth of an acid-fast organism is observed 
after two to four days of incubation. The 
colonies of this bacterium appear smooth and 
hemispherical, usually with a butyrous or 
waxy consistency. Colonies are typically 
nonchromogenic but may appear off-white or 
faintly cream-color. To separate M fortiutum 
and M chelonae, M chelonae does not reduce 
nitrates, incapable assimilating iron from 
ferric ammonium citrate, resistant to 
ciprofloxacin and pipemidic acid, but 
sensitive to polymyxin B; M fortiutum has the 
opposite reactions1,2,12. Adequate and proper 
specimen collection together with notifying 
the microbiologist will enhance isolation and 
identification of the microorganism. In cases 
of cutaneous infection biopsy or aspiration 
materials are better than swab. Erythrocyte 
sedimentation rate or C-reactive protein may 
be helpful to differentiate colonizer and 
pathogen, but these are nonspecific tests and 
the results must be carefully evaluated within 
the clinical context of the patient9,13. 
Histological findings may reveal presence of 
acute inflammatory cells, microabscesses, 
granulomatous inflammation, or granulomas 
(with or without caseation). These findings  
 
may be mixed. However, special tissue stains 
for AFB may reveal organisms2,14. 
These organisms are difficult to treat once 
true infection is diagnosed and documented.  
This explains why the disease was took long 
time to be eradicated in our patients. Most 
information regarding treatment of M 
chelonae infection is derived from case 
reviews and expert opinion. Definitive 
statements regarding diagnosis and treatment 
are often lacking9. Tobramycin, 
clarithromycin, imipenem, and amikacin are 
drugs of choice for treatment infections 
related to the M chelonae. The treatment of 
localized infections due to M. chelonae is 
currently managed by using the newer 
macrolide clarithromycin as the cornerstone 
of therapy. However, more serious disease 
should be treated, for at least the first two 
weeks, with clarithromycin in combination 
with one of the injectable agents. This is why 
we opted to add ceftazideme to clarithromycin 
in our patients. For serious disseminated 
infections involving M. chelonae, the 
injectable agents as tobramycin plus 
imipenem have been used for the first two to 
six weeks in combination with clarithromycin 
to avoid or minimize the development of drug 
resistance to the macrolide. Relapses may 
occur especially with those 
immunocompromised cases. We didn't use 
tobramycin for fear of drug toxicity 
particularly in prolonged usage of drugs. On 
the other hand, newer oral agents such as 
gatifloxacin and/or linezolid are promising for 
use in combination with clarithromycin. 
However, there is little experience with these 
newer agents 
The lesson of this paper is that postoperative 
patients who show poor healing of the 
surgical site or indwelling infection not 
responsive to empiric antibiotics and regular 
dressings should have careful screening for 
M. chelonae. Also, patients with erythema, 
tenderness, and chronic discharge of the 
surgical incision that does not result in 
positive routine cultures should be cultured 
specifically for M. chelonae and wound 
tissues should be sent for histopathological  
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investigation. Performed Zeihl-Neelsen (ZN) 
stain may show acid fast bacilli. Materials 
should be cultured on Lowenstein-Jensen (LJ) 
medium and incubated at 35°C. Culture on LJ 
medium showed non pigmented colonies after 
4th day of incubation, which is presumptively 
identified as a rapidly growing non-
tuberculosis mycobacterium as shown in Fig 
1. For further identification, various 
biochemical tests can be done to identify the 
species of rapid Growing Mycobacterium. 
The definite identification of the organism as 
M chelonae was based on various test such as; 
growth at 25°C and 37°C not at 42° C, 
arylsulphatase, urease, 68°C catalase test, 
negative nitrate reduction test and tolerance to 
5% NaCl.  
         To our knowledge this is first report on 
M Chelonae related wound infection reported 
in Sudan. To identify possible source of 
microorganism environmental, disinfectant 
and water sampling should be carried out. We 
recommend that physician to think possibility 
of M chelonae related wound infection 
especially when they face poor healing 
chronic surgical site which is not responding 
to broad spectrum of antibiotics.   
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